top of page

Fact Sheet III


  • The FDA has officially named two psychedelics "breakthrough therapies," MDMA for PTSD and psilocybin for treatment-resistant depression

  • Psychedelics are not designed for daily use; they are often one-off treatments, making them especially cost-effective

  • More than $500bn per year is spent on prescription psychiatric meds in the USA alone; psychedelics can help us cut healthcare costs

Business Meeting
Fact Sheet III: Projects
bottom of page